A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Condition Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung Cancer Estimated Enrollment: 24 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MORAb-009-001 Study First Received: May 11, 2006 Last Updated: July 16, 2014 Estimated Primary Completion Date: September 2008 Primary Outcome Measures: Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by Investigator Sponsors and...
Continue reading